Immunotherapeutic intervention against sarcomas

Research output: Contribution to journalArticle

Abstract

Advances in systemic therapy for sarcoma have produced, over the last two decades, relatively short-term benefits for the majority of patient. Among the novel biologic therapeutics that will likely increase our ability to cure human cancer in the years to come, immunotherapy is one of the most promising approaches. While past attempts to use immunotherapy have failed to dramatically shift the paradigm of care for the treat-ment of patients with sarcoma, major advances in basic and translational research have resulted, in more recent years, in clinical trial activity that is now beginning to generate promising results. However, to move from "proof of principle" to large scale clinical ap-plicability, we need well-designed, multi-institutional clinical trials, along with contin-uous laboratory research to explore further the immunological characteristics of indi-vidual sarcoma subtypes and the consequent tailoring of therapy.

Original languageEnglish
Pages (from-to)350-356
Number of pages7
JournalJournal of Cancer
Volume2
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Sarcoma
Immunotherapy
Clinical Trials
Translational Medical Research
Therapeutics
Research
Neoplasms

Keywords

  • Immunotherapy
  • Sarcoma

ASJC Scopus subject areas

  • Oncology

Cite this

Immunotherapeutic intervention against sarcomas. / Pedrazzoli, Paolo; Secondino, Simona; Perfetti, Vittorio; Comoli, Patrizia; Montagna, Daniela.

In: Journal of Cancer, Vol. 2, No. 1, 2011, p. 350-356.

Research output: Contribution to journalArticle

@article{8f3113a01a70466c9cd55960168bcb0e,
title = "Immunotherapeutic intervention against sarcomas",
abstract = "Advances in systemic therapy for sarcoma have produced, over the last two decades, relatively short-term benefits for the majority of patient. Among the novel biologic therapeutics that will likely increase our ability to cure human cancer in the years to come, immunotherapy is one of the most promising approaches. While past attempts to use immunotherapy have failed to dramatically shift the paradigm of care for the treat-ment of patients with sarcoma, major advances in basic and translational research have resulted, in more recent years, in clinical trial activity that is now beginning to generate promising results. However, to move from {"}proof of principle{"} to large scale clinical ap-plicability, we need well-designed, multi-institutional clinical trials, along with contin-uous laboratory research to explore further the immunological characteristics of indi-vidual sarcoma subtypes and the consequent tailoring of therapy.",
keywords = "Immunotherapy, Sarcoma",
author = "Paolo Pedrazzoli and Simona Secondino and Vittorio Perfetti and Patrizia Comoli and Daniela Montagna",
year = "2011",
doi = "10.7150/jca.2.350",
language = "English",
volume = "2",
pages = "350--356",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "1",

}

TY - JOUR

T1 - Immunotherapeutic intervention against sarcomas

AU - Pedrazzoli, Paolo

AU - Secondino, Simona

AU - Perfetti, Vittorio

AU - Comoli, Patrizia

AU - Montagna, Daniela

PY - 2011

Y1 - 2011

N2 - Advances in systemic therapy for sarcoma have produced, over the last two decades, relatively short-term benefits for the majority of patient. Among the novel biologic therapeutics that will likely increase our ability to cure human cancer in the years to come, immunotherapy is one of the most promising approaches. While past attempts to use immunotherapy have failed to dramatically shift the paradigm of care for the treat-ment of patients with sarcoma, major advances in basic and translational research have resulted, in more recent years, in clinical trial activity that is now beginning to generate promising results. However, to move from "proof of principle" to large scale clinical ap-plicability, we need well-designed, multi-institutional clinical trials, along with contin-uous laboratory research to explore further the immunological characteristics of indi-vidual sarcoma subtypes and the consequent tailoring of therapy.

AB - Advances in systemic therapy for sarcoma have produced, over the last two decades, relatively short-term benefits for the majority of patient. Among the novel biologic therapeutics that will likely increase our ability to cure human cancer in the years to come, immunotherapy is one of the most promising approaches. While past attempts to use immunotherapy have failed to dramatically shift the paradigm of care for the treat-ment of patients with sarcoma, major advances in basic and translational research have resulted, in more recent years, in clinical trial activity that is now beginning to generate promising results. However, to move from "proof of principle" to large scale clinical ap-plicability, we need well-designed, multi-institutional clinical trials, along with contin-uous laboratory research to explore further the immunological characteristics of indi-vidual sarcoma subtypes and the consequent tailoring of therapy.

KW - Immunotherapy

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84875713143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875713143&partnerID=8YFLogxK

U2 - 10.7150/jca.2.350

DO - 10.7150/jca.2.350

M3 - Article

AN - SCOPUS:84875713143

VL - 2

SP - 350

EP - 356

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 1

ER -